Irene Garces

Irene Garces

Auto-generated profile, based on publicly available information

Irene Garces

Department of Immunobiochemistry Mannheim Institute for Innate Immunoscience (MI3) Medical Faculty Mannheim Heidelberg University 68167 Mannheim Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
DRDeepak Raj
Deepak Raj
MNMaria Nikolaidi
Maria Nikolaidi
IGIrene Garces
Irene Garces
DLDaniela Lorizio
Daniela Lorizio
NCNatalia M. Castro
Natalia M. Castro
JMJohn Marshall
John Marshall
Purpose: To investigate whether CEACAM7 represents a novel therapeutic target for treating pancreatic ductal adenocarcinoma (PDAC) and to generate CEACAM7-targeting CAR T cells to test this hypothesis. Experimental Design: We identified CEACAM7 (CGM2), a member of the CEA family of proteins with expression restricted to the colon and pancreas, as a potential CAR T-cell target for PDAC. We probed a panel of PDAC tumor sections as well as patient-derived PDAC cell cultures for CEACAM7 expression. We generated CAR-targeting CEACAM7, and assessed antitumor efficacy of CEACAM7 CAR T cells using in vitro and in vivo models. Results: We show here that CEACAM7 is expressed in a large subset of PDAC tumors, with low to undetectable expression in all normal tissues tested. CEACAM7 is also expressed in primary PDAC cultures isolated from patient-derived tumors, with high expression within the cancer stem cell-enriched subset. CAR T cells targeting CEACAM7 are capable of targeting antigen-expressing tumor cells, and mediate remission in patient-derived xenograft tumors. Conclusions: We identify CEACAM7 as a potential therapeutic target in PDAC and describe the development of CEACAM7-targeted CAR T cells with efficacy against PDAC.

1 July 2024 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
THTomáš Hofman
Tomáš Hofman
SNSiu Wang Ng
Siu Wang Ng
IGIrene Garcés-Lázaro
Irene Garcés-Lázaro
FHFlorian Heigwer
Florian Heigwer
MBMichael Boutros
Michael Boutros
ACAdelheid Cerwenka
Adelheid Cerwenka
Background: Immune checkpoint blockade targeting the adaptive immune system has revolutionized the treatment of cancer. Despite impressive clinical benefits observed, patient subgroups remain non-responsive underscoring the necessity for combinational therapies harnessing additional immune cells. Natural killer (NK) cells are emerging tools for cancer therapy. However, only subpopulations of NK cells that are differentially controlled by inhibitory receptors exert reactivity against particular cancer types. How to leverage the complete anti-tumor potential of all NK cell subsets without favoring the emergence of NK cell-resistant tumor cells remains unresolved. Methods: We performed a genome-wide CRISPR/Cas9 knockout resistance screen in melanoma cells in co-cultures with human primary NK cells. We comprehensively evaluated factors regulating tumor resistance and susceptibility by focusing on NK cell subsets in an allogenic setting. Moreover, we tested therapeutic blocking antibodies currently used in clinical trials. Results: Melanoma cells deficient in antigen-presenting or the IFNγ-signaling pathways were depleted in remaining NK cell-co-cultured melanoma cells and displayed enhanced sensitivity to NK cells. Treatment with IFNγ induced potent resistance of melanoma cells to resting, IL-2-cultured and ADCC-activated NK cells that depended on B2M required for the expression of both classical and non-classical MHC-I. IFNγ-induced expression of HLA-E mediated the resistance of melanoma cells to the NKG2A+ KIR− and partially to the NKG2A+ KIR+ NK cell subset. The expression of classical MHC-I by itself was sufficient for the inhibition of the NKG2A− KIR+, but not the NKG2A+ KIR+ NK cell subset. Treatment of NK cells with monalizumab, an NKG2A blocking mAb, enhanced the reactivity of a corresponding subset of NK cells. The combination of monalizumab with lirilumab, blocking KIR2 receptors, together with DX9, blocking KIR3DL1, was required to restore cytotoxicity of all NK cell subsets against IFNγ-induced resistant tumor cells in melanoma and tumors of different origins. Conclusion: Our data reveal that in the context of NK cells, IFNγ induces the resistance of tumor cells by the upregulation of classical and non-classical MHC-I. Moreover, we reveal insights into NK cell subset reactivity and propose a therapeutic strategy involving combinational monalizumab/lirilumab/DX9 treatment to fully restore the antitumor response across NK cell subsets.

21 April 2025 in Small Methods
Verified
Journal Article
Open access
FAFlorian Aubermann
Florian Aubermann
SSSenne Seneca
Senne Seneca
THTomáš Hofman
Tomáš Hofman
IGIrene Garcés‐Lázaro
Irene Garcés‐Lázaro
KAKarim Ajmail
Karim Ajmail
JSJoachim Pius Spatz
Joachim Pius Spatz
Natural Killer (NK) cells, as key effector cells of the innate immune system, display high heterogeneity in their ability to kill target cells. The underlying mechanisms remain poorly understood. Here, a droplet‐based microfluidic platform is presented to identify and select NK cells with serial killing ability. To this end, primary human NK cells are encapsulated with several target cells using an efficient negative pressure‐based droplet generator. Capitalizing on the large number of possible killing events due to quantization into droplets, a convolutional neural network analysis pipeline is developed to quantify the cytotoxicity and abundance of serial killing events with high accuracy. To physically select NK cells based on their serial killing ability, MultiCell‐Sort ‐ an advanced real‐time image‐based droplet sorting module ‐ is presented. While conventional single‐cell sorters mostly evaluate intrinsically‐encoded properties, such as protein expression levels, MultiCell‐Sort can select living NK cells based on complex functional phenotypes emerging from multiple cell‐cell interactions within the droplet. This novel microfluidic phenotyping platform hereby allows the potential integration of complementary techniques to provide an understanding of regulators and markers underlying the heterogeneous nature of NK cell functional phenotypes.

31 March 2023
Verified
Other
Open access
DRDeepak Raj
Deepak Raj
MNMaria Nikolaidi
Maria Nikolaidi
IGIrene Garces
Irene Garces
DLDaniela Lorizio
Daniela Lorizio
NCNatalia M. Castro
Natalia M. Castro
JMJohn F. Marshall
John F. Marshall
Analysis of CAR T-cells transduced or untransduced with 2869 CAR

31 March 2023
Verified
Other
Open access
DRDeepak Raj
Deepak Raj
MNMaria Nikolaidi
Maria Nikolaidi
IGIrene Garces
Irene Garces
DLDaniela Lorizio
Daniela Lorizio
NCNatalia M. Castro
Natalia M. Castro
JMJohn F. Marshall
John F. Marshall
Purpose:To investigate whether CEACAM7 represents a novel therapeutic target for treating pancreatic ductal adenocarcinoma (PDAC) and to generate CEACAM7-targeting CAR T cells to test this hypothesis.Experimental Design:We identified CEACAM7 (CGM2), a member of the CEA family of proteins with expression restricted to the colon and pancreas, as a potential CAR T-cell target for PDAC. We probed a panel of PDAC tumor sections as well as patient-derived PDAC cell cultures for CEACAM7 expression. We generated CAR-targeting CEACAM7, and assessed antitumor efficacy of CEACAM7 CAR T cells using in vitro and in vivo models.Results:We show here that CEACAM7 is expressed in a large subset of PDAC tumors, with low to undetectable expression in all normal tissues tested. CEACAM7 is also expressed in primary PDAC cultures isolated from patient-derived tumors, with high expression within the cancer stem cell-enriched subset. CAR T cells targeting CEACAM7 are capable of targeting antigen-expressing tumor cells, and mediate remission in patient-derived xenograft tumors.Conclusions:We identify CEACAM7 as a potential therapeutic target in PDAC and describe the development of CEACAM7-targeted CAR T cells with efficacy against PDAC.

31 March 2023
Verified
Other
Open access
DRDeepak Raj
Deepak Raj
MNMaria Nikolaidi
Maria Nikolaidi
IGIrene Garces
Irene Garces
DLDaniela Lorizio
Daniela Lorizio
NCNatalia M. Castro
Natalia M. Castro
JMJohn F. Marshall
John F. Marshall
Purpose:To investigate whether CEACAM7 represents a novel therapeutic target for treating pancreatic ductal adenocarcinoma (PDAC) and to generate CEACAM7-targeting CAR T cells to test this hypothesis.Experimental Design:We identified CEACAM7 (CGM2), a member of the CEA family of proteins with expression restricted to the colon and pancreas, as a potential CAR T-cell target for PDAC. We probed a panel of PDAC tumor sections as well as patient-derived PDAC cell cultures for CEACAM7 expression. We generated CAR-targeting CEACAM7, and assessed antitumor efficacy of CEACAM7 CAR T cells using in vitro and in vivo models.Results:We show here that CEACAM7 is expressed in a large subset of PDAC tumors, with low to undetectable expression in all normal tissues tested. CEACAM7 is also expressed in primary PDAC cultures isolated from patient-derived tumors, with high expression within the cancer stem cell-enriched subset. CAR T cells targeting CEACAM7 are capable of targeting antigen-expressing tumor cells, and mediate remission in patient-derived xenograft tumors.Conclusions:We identify CEACAM7 as a potential therapeutic target in PDAC and describe the development of CEACAM7-targeted CAR T cells with efficacy against PDAC.